JP2016514162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514162A5 JP2016514162A5 JP2016503050A JP2016503050A JP2016514162A5 JP 2016514162 A5 JP2016514162 A5 JP 2016514162A5 JP 2016503050 A JP2016503050 A JP 2016503050A JP 2016503050 A JP2016503050 A JP 2016503050A JP 2016514162 A5 JP2016514162 A5 JP 2016514162A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- mixture
- less
- laquinimod sodium
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 145
- 229960004577 laquinimod Drugs 0.000 claims 145
- 239000000203 mixture Substances 0.000 claims 104
- 238000004128 high performance liquid chromatography Methods 0.000 claims 46
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 claims 24
- 239000002245 particle Substances 0.000 claims 24
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 21
- 229910052708 sodium Inorganic materials 0.000 claims 21
- 239000011734 sodium Substances 0.000 claims 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 18
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 16
- ZFPGGAUWFSIDEL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methylquinolin-2-one Chemical compound C1=CC(Cl)=C2C(O)=CC(=O)N(C)C2=C1 ZFPGGAUWFSIDEL-UHFFFAOYSA-N 0.000 claims 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000012535 impurity Substances 0.000 claims 8
- PAIDZDPOJWEZLX-UHFFFAOYSA-N methyl 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OC)=C(O)C2=C1Cl PAIDZDPOJWEZLX-UHFFFAOYSA-N 0.000 claims 7
- 229910001385 heavy metal Inorganic materials 0.000 claims 6
- 238000005443 coulometric titration Methods 0.000 claims 5
- 238000002425 crystallisation Methods 0.000 claims 5
- 230000008025 crystallization Effects 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 4
- FTBWKSJUFWRKGL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=C2C(O)=C(C(O)=O)C(=O)N(C)C2=C1 FTBWKSJUFWRKGL-UHFFFAOYSA-N 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 3
- 229910052782 aluminium Inorganic materials 0.000 claims 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- YFDWFVLGERLACT-UHFFFAOYSA-N n-ethyl-4,5-dihydroxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(O)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 YFDWFVLGERLACT-UHFFFAOYSA-N 0.000 claims 3
- 229910052725 zinc Inorganic materials 0.000 claims 3
- 239000011701 zinc Substances 0.000 claims 3
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims 2
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 claims 2
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims 2
- POQZLXDTXDVHMY-UHFFFAOYSA-N ethyl 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OCC)=C(O)C2=C1Cl POQZLXDTXDVHMY-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- NDCFBPDNHOZORS-UHFFFAOYSA-N 1,2-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2NCC(C(=O)O)=CC2=C1 NDCFBPDNHOZORS-UHFFFAOYSA-N 0.000 claims 1
- BZKCTVZVKAXVFH-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(Cl)=C2C(O)=C1C(=O)NC1=CC=CC=C1 BZKCTVZVKAXVFH-UHFFFAOYSA-N 0.000 claims 1
- LVJRRJLPMQHXBY-UHFFFAOYSA-N 5-chloro-n-ethyl-3-hydroxy-1-methyl-2,4-dioxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(Cl)=C2C(=O)C1(O)C(=O)N(CC)C1=CC=CC=C1 LVJRRJLPMQHXBY-UHFFFAOYSA-N 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- -1 methyl (2,3,4,5,6-pentahydroxyhexyl) amino Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785575P | 2013-03-14 | 2013-03-14 | |
| US61/785,575 | 2013-03-14 | ||
| PCT/US2014/029292 WO2014153145A2 (en) | 2013-03-14 | 2014-03-14 | Crystals of laquinimod sodium and improved process for the manufacture thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514162A JP2016514162A (ja) | 2016-05-19 |
| JP2016514162A5 true JP2016514162A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
Family
ID=50631081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503050A Withdrawn JP2016514162A (ja) | 2013-03-14 | 2014-03-14 | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013521305A (ja) * | 2010-03-03 | 2013-06-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いるループス関節炎の治療 |
| TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201591699A1 (ru) * | 2013-03-14 | 2016-02-29 | Тева Фармасьютикал Индастриз Лтд. | Кристаллы лаквинимода натрия и улучшенный способ их производства |
| US20150306088A1 (en) | 2014-04-29 | 2015-10-29 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CN107966506B (zh) * | 2017-11-20 | 2019-09-13 | 福州大学 | 一种橡胶及橡胶制品中n-乙基苯胺含量的检测方法 |
| KR102069868B1 (ko) * | 2018-02-28 | 2020-01-23 | 고려대학교 산학협력단 | 합성가스 발효 균의 합성가스 발효 시의 대사체 분석을 위한 대사체 샘플링 및 분석 방법 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US607785A (en) | 1898-07-19 | Ore-car | ||
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
| TW376491B (en) | 1991-06-22 | 1999-12-11 | Fuji Xerox Co Ltd | Image processing system with a buffer memory |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6256814B1 (en) | 1997-09-19 | 2001-07-10 | Cosco Management, Inc. | Playyard |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| CN100390148C (zh) | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
| JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| RU2404746C2 (ru) | 2005-02-23 | 2010-11-27 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина с улучшенной однородностью содержимого |
| EP1902034B1 (en) | 2005-06-02 | 2011-03-30 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| SI1937642T1 (sl) | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevega lakvinimoda in postopek za njihovo pripravo |
| AU2007227609A1 (en) | 2006-03-16 | 2007-09-27 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
| HRP20120093T1 (hr) | 2006-06-12 | 2012-03-31 | Teva Pharmaceutical Industries Limited | Postojani pripravci lakvinimoda |
| JP5216769B2 (ja) | 2006-08-17 | 2013-06-19 | ザ・ユニバーシティ・オブ・シカゴ | 炎症性疾患の処置 |
| EP2214657A1 (en) | 2007-10-23 | 2010-08-11 | UCB Pharma GmbH | Compounds for treating demyelination conditions |
| SI2234485T1 (sl) * | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| EP2318371A2 (en) | 2008-07-01 | 2011-05-11 | Actavis Group PTC EHF | Novel solid state forms of laquinimod and its sodium salt |
| EA021227B1 (ru) | 2008-09-03 | 2015-05-29 | Тева Фармасьютикал Индастриз Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| US8598203B2 (en) | 2009-07-30 | 2013-12-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of Crohn's disease with laquinimod |
| CA2771203C (en) | 2009-08-10 | 2019-04-09 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| JP2013521305A (ja) | 2010-03-03 | 2013-06-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いるループス関節炎の治療 |
| BR112012022187A2 (pt) | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| ES2558556T3 (es) | 2010-03-03 | 2016-02-05 | Teva Pharmaceutical Industries Ltd. | Tratamiento de nefritis lúpica usando laquinimod |
| PE20130396A1 (es) | 2010-07-09 | 2013-04-19 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma |
| EP2590653A4 (en) * | 2010-07-09 | 2014-01-01 | Teva Pharma | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| MX2013006464A (es) | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
| KR101130582B1 (ko) | 2011-06-07 | 2012-03-30 | 이대영 | 조립식 건축구조물의 골조연결장치 |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| BR112014002095A2 (pt) | 2011-07-28 | 2017-02-21 | Teva Pharma | tratamento de esclerose múltipla com combinação de laquinimod e acetato de glatiramer |
| KR20140054129A (ko) | 2011-07-28 | 2014-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료 |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途 |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201347762A (zh) | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201591699A1 (ru) * | 2013-03-14 | 2016-02-29 | Тева Фармасьютикал Индастриз Лтд. | Кристаллы лаквинимода натрия и улучшенный способ их производства |
-
2014
- 2014-03-14 EA EA201591699A patent/EA201591699A1/ru unknown
- 2014-03-14 SG SG11201506409RA patent/SG11201506409RA/en unknown
- 2014-03-14 JP JP2016503050A patent/JP2016514162A/ja not_active Withdrawn
- 2014-03-14 EP EP14721137.9A patent/EP2970129A2/en not_active Withdrawn
- 2014-03-14 US US14/214,191 patent/US9233927B2/en not_active Expired - Fee Related
- 2014-03-14 TW TW103109454A patent/TW201519892A/zh unknown
- 2014-03-14 KR KR1020157029570A patent/KR20150143499A/ko not_active Withdrawn
- 2014-03-14 MX MX2015011627A patent/MX2015011627A/es unknown
- 2014-03-14 PE PE2015001974A patent/PE20151935A1/es not_active Application Discontinuation
- 2014-03-14 CA CA2901849A patent/CA2901849A1/en not_active Abandoned
- 2014-03-14 NZ NZ630427A patent/NZ630427A/en not_active IP Right Cessation
- 2014-03-14 AU AU2014236232A patent/AU2014236232A1/en not_active Abandoned
- 2014-03-14 BR BR112015021602A patent/BR112015021602A2/pt not_active IP Right Cessation
- 2014-03-14 HK HK16107245.0A patent/HK1220444A1/zh unknown
- 2014-03-14 HK HK16104113.6A patent/HK1216311A1/zh unknown
- 2014-03-14 CN CN201480014512.1A patent/CN105051013A/zh active Pending
- 2014-03-14 WO PCT/US2014/029292 patent/WO2014153145A2/en not_active Ceased
- 2014-03-14 US US14/773,683 patent/US20160046582A1/en not_active Abandoned
- 2014-03-17 AR ARP140101184A patent/AR095562A1/es unknown
-
2015
- 2015-08-04 IL IL240356A patent/IL240356A0/en unknown
- 2015-09-14 CL CL2015002712A patent/CL2015002712A1/es unknown
- 2015-12-03 US US14/958,396 patent/US20160158216A1/en not_active Abandoned
-
2017
- 2017-08-01 US US15/666,259 patent/US20170327464A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514162A5 (cg-RX-API-DMAC7.html) | ||
| JP7372255B2 (ja) | 免疫調節剤としての複素環式化合物 | |
| TWI274754B (en) | Purine derivatives, pharmaceutical composition for the treatment of a condition mediated by SYK kinase comprising the same and process for the preparation thereof | |
| JP7269917B2 (ja) | Ａｈｒ阻害剤およびその使用 | |
| JP4790703B2 (ja) | 環式化合物 | |
| JP2009529496A (ja) | 誘導型一酸化窒素シンターゼ抑制剤として有用なキノロン類 | |
| JP2022502476A (ja) | インドールａｈｒ阻害剤およびその使用 | |
| CN109563081A (zh) | 可用作蛋白调节剂的杂环酰胺类 | |
| IL295649A (en) | Heterocyclic amides useful as protein modulators | |
| TW201736372A (zh) | Pde1抑制劑 | |
| WO2019100061A1 (en) | Oxoacridinyl acetic acid derivatives and methods of use | |
| EP2139881B1 (en) | Quinolines and their therapeutic use | |
| AU597996B2 (en) | New 1H,3H-pyrrolo{1,2-c}thiazole derivatives, preparation thereof and pharmaceutical compositions containing them | |
| EP1534687B1 (en) | 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators | |
| JP7300552B2 (ja) | 縮合環ピリミジンアミノ化合物、その調製方法、医薬組成物及び使用 | |
| TW201211006A (en) | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | |
| AU2003282263A1 (en) | Imidazoquinoline derivatives as adenosine a3 receptor ligands | |
| WO2017114446A1 (zh) | 艾沙度林的新晶型及其制备方法 | |
| JP2007516950A (ja) | プロスタグランジンｅ２アゴニストまたはアンタゴニストであるオルニチン誘導体 | |
| CN103193864B (zh) | 培哚普利的精氨酸盐的δ晶型、其制备方法和包含它的药物组合物 | |
| WO2007017264A2 (en) | Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders | |
| JP2004508352A (ja) | 置換縮合ピロールイミン及びピラゾールイミン | |
| WO2023160475A1 (zh) | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 | |
| TW202408538A (zh) | Stat降解劑及其用途 | |
| US20250136579A1 (en) | Salts and free bases of bifunctional compound and polymorph forms thereof |